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Introduction: Hormone-related reproductive factors have been reported to be associated with 
breast cancer subtypes. However, the direction and magnitude of these associations were 
inconsistent. Additionally, for breast cancer defined by estrogen receptor (ER) and progesterone 
receptor (PR): ER+PR+, ER+PR-, ER-PR+, and ER-PR- subtypes, no meta-analysis was 
available for ER+PR-and ER-PR+ subtypes. For ER+PR+ and ER-PR- subtypes, only a few 
reproductive risk factors have been examined in meta-analyses.  
Methods: Primary studies published from 2011 to 2017 were retrieved from PubMed, Embase, 
and Scopus. Following PRISMA guidelines, a total of 98 eligible studies investigated the 
association between reproductive factors and breast cancer subtypes. Among these 98 studies, 27 
were included in the meta-analysis regarding the association between reproductive factors and 
ERPR subtypes. Odds ratios (OR), relative risks (RR), and hazard ratios (HR) were extracted for 
reproductive factors, including age at menarche, age at menopause, menopausal status, 
pregnancy, age at first birth, parity, breastfeeding, years since last birth, OC use, and HRT. OR 
and HR were converted to RR to ensure consistency. A meta-analysis with a random effect 
model was separately conducted for each combination of a reproductive factor and a BC subtype 
defined by ERPR status. Heterogeneity across studies was examined by I2-statistic, publication 
bias was examined utilizing Egger and Begg’s test. 
Results: This meta-analysis observed that late age at menarche was associated with a reduced 
risk for ER+PR+ (RR:0.79, 95% CI: 0.72, 0.85), ER+PR- (RR:0.75, 95% CI:0.58, 0.92), ER-
PR+ (RR: 0.79, 95% CI:0.63, 0.95), and ER-PR- subtypes (RR:0.85, 95% CI: 0.79, 0.91). Ever 
versus never pregnancy was associated with a statistically significant reduced risk of ER+PR+ 
(RR: 0.62, 95% CI: 0.47, 0.78), ER+PR- (RR: 0.70, 95% CI: 0.57, 0.83), and ER-PR+ subtypes 
(RR: 0.68, 95% CI: 0.49, 0.87). Ever versus never breastfeeding was associated with a 
statistically significant reduced risk of ER+PR+ (RR: 0.87, 95% CI: 0.79, 0.96), ER+PR- (RR: 
0.67, 95% CI: 0.52, 0.83), and ER-PR- subtypes (RR: 0.81, 95% CI: 0.69, 0.93). No significant 
results were observed for years since last birth and oral contraceptive use. Additionally, results 
were relatively less consistent for age at menopause, menopausal status, age at first birth, parity, 
and hormone replacement therapy. There was no evidence of publication bias for pregnancy and 
parity. For the rest reproductive factors, there is some evidence of publication bias.  
Conclusion: The patterns of reproductive factors differ by ERPR status. Most significant 
associations were observed for ER+PR+ and ER+PR- subtypes. Moreover, strongest associations 
were mostly observed in ER+PR- subtype. Thus, breast cancer preventive guideline regarding 
reproductive factors probably should be revised by subtypes. Moreover, ever breastfeeding and 
pregnancy could probably be added to breast cancer risk calculation model, although more 
prospective studies with a large sample size are needed to confirm the findings.
1. Background 
Breast cancer (BC) is globally one of the most common cancers and one of the leading causes of 
cancers death among women1. The worldwide estimated incidence of female BC by 2050 is 3.2 
million new cases per year2. Different patterns of reproductive factors, lifestyle-related factors, 
genetic factors, and BC screening have been reported to cause the BC incidence increase3. BC is 
widely recognized as a heterogeneous cancer due to its different risk factors, prognoses, and 
treatments by subtypes4. Common reproductive factors include age at menarche, age at 
menopause, menopausal status, pregnancy-related factors, age at first birth, parity, breastfeeding, 
years since last birth, OC use, and hormone replacement therapy (HRT). These factors probably 
impact BC subtypes through hormone such as estrogen5. Generally, age at first birth, pregnancy 
change hormone status. Some other factors such as age at menarche and age at menopause are 
markers for hormone status changes. Detailly, earlier age at menarche and later age at 
menopause might cause a longer duration of hormone exposure, which is generally believed to 
increase risk of BC6. According to estrogen receptor (ER) and progesterone receptor (PR), BC 
could be classified as ER+PR+ subtype, ER+PR- subtype, ER-PR+ subtype, and ER-PR- 
subtype. Among these four subtypes, ER+PR+ subtype is the most common one, and ER-PR+ 
subtype is least common, with ER-PR- and ER+PR- in the middle7-9. Associations have been 
investigated between reproductive factors and BC subtypes classified by ERPR status. However, 
the influences of many reproductive factors on these subtypes are controversial. For instance, 
according to a systematic review conducted by Anderson et al, lactation was inversely associated 
with hormone receptor positive BC only in five out of 18 studies3. According to expressions of 
ER, PR, and human epidermal growth factor receptor-2 (HER2), BC could be classified into 
luminal A, luminal B, HER2-overexpressing, and triple-negative (TN) BC10, 11. Associations 
between reproductive factors and these subtypes, especially HER2-overexpressing and TN BC, 
have not been well established3. For example, Yang et al found higher parity was associated with 
an increased risk of HER2-overexpressing BC12; however, Ma et al found the opposite 
association13. 
It is unclear to what extent impacts of reproductive factors have on each subtype. To date, no 
thorough meta-analysis has summarized available studies about associations between 
reproductive factors and BC subtypes. Specifically, among four subtypes defined by ERPR 
status, associations between reproductive factors and ER-PR- BC has been summarized in a few 
meta-analysis14-16; however, ER+PR+ subtype has only been evaluated in one of them16. 
Additionally, no review is available for both the association between reproductive factors and 
ER+PR- subtype and the association between reproductive factors and ER-PR+ subtype. 
Similarly, for luminal A, luminal B, HER2-overexpressing, and TN BC, only a few meta-
analyses summarized some of these subtypes with limited types of reproductive factors4, 14, 15, 17. 
The most recent meta-analysis published in 2017 only investigated the association between oral 
contraceptive (OC) use and TN BC17. Another meta-analysis conducted in 2016, focusing on 
associations between reproductive factors and BC subtypes, only researched parity, age at first 
birth, and breastfeeding4. 
Due to impacts reproductive factors have on BC incidence, prognoses, and treatment, 
inconsistent findings on associations between reproductive factors and BC subtypes, and no 
thorough meta-analysis of these associations, conducting a meta-analysis about these 
associations is crucial. It allows us to have a review of how papers researched all reproductive 
risk factors by different subtypes, to explore the magnitude and direction of these associations, to 
better understand BC etiology based on subtypes, and to provide a theoretical foundation for 
future research, and to propose potential BC preventive strategies. 
 
2. METHODS 
PRISMA guidelines (Fig. 1) were followed for this systematic review and meta-analysis18. 
Primary studies with the subject as human and published in English from January 1st, 2000 to 
December 31st, 2017 were retrieved from PubMed, Scopus, and Embase. The search strategy 
utilized included MeSH and non-MeSH key terms: 1) “reproductive history” as a MeSH term in 
general as well as specific reproductive factors, including risk factors, menarche, menopause, 
menstruation, menstrual period, age at first birth, birth control, parity, family size, pregnancy, 
pregnan*,  birth intervals, breastfeeding, contraceptives, and hormone replacement therapy, 
2)“Breast Neoplasms” and its relevant permutations and abbreviations, 3) “subtypes”: receptors, 
estrogen; receptors, progesterone; receptors, androgen; pidermal growth factor; luminal A; 
luminal B; HER-2; basal-like; and triple negative breast neoplasms. The specific search strategy 
is the following: 
(((((((((((((((((("Reproductive History"[Mesh]) OR (((("Contraceptive Agents, Female"[Mesh]) 
OR ((contraceptive*[Title/Abstract] OR "birth control"[Title/Abstract] OR 
contraception[Title/Abstract]))) OR (("birth control"[Title/Abstract]) AND pill*[Title/Abstract])) 
OR "family planning"[Title/Abstract])) OR (((((("Gravidity"[Mesh]) OR "Parity"[Mesh]) OR 
parity[Title/Abstract]) OR gravidity[Title/Abstract]) OR "family size"[Title/Abstract]) OR 
"pregnan*"[Title/Abstract])) OR (((((("pregnancy timing"[Title/Abstract]) OR "timing of 
pregnancies"[Title/Abstract])) OR "Birth Intervals"[Mesh])) OR "birth 
intervals"[Title/Abstract])) OR (("Maternal Age"[Mesh]) OR "age at first 
birth"[Title/Abstract]))) OR ((("Breast Feeding"[Mesh]) OR ((breastfeed*[Title/Abstract] OR 
breastfed[Title/Abstract]))) OR (("breast feeding"[Title/Abstract] OR "breast 
feed"[Title/Abstract])))) OR (((("Menarche"[Mesh]) OR "first period"[Title/Abstract]) OR 
menarche[Title/Abstract]) OR ((menstruation[Title/Abstract] OR menstrual[Title/Abstract] OR 
periods[Title/Abstract])))) OR (("Menopause"[Mesh]) OR menopaus*[Title/Abstract])) OR 
(("Hormone Replacement Therapy"[Mesh]) OR (("hormone replacement 
therapy"[Title/Abstract] OR HRT[Title/Abstract]))))))) OR ((reproductive[Title/Abstract]) AND 
((risk factors[MeSH Terms]) OR ((risks[Title/Abstract] OR "risk factors"[Title/Abstract] OR 
"risk factor"[Title/Abstract])))))) OR ((premenopaus*[Title/Abstract] OR 
postmenopaus*[Title/Abstract])))) 
AND ((((((((((("Breast Neoplasms"[Mesh]) OR (("breast cancer"[Title/Abstract]) OR "breast 
neoplasms"[Title/Abstract]))) 
AND ((((((((((((("Receptors, Estrogen"[Mesh]) OR (("estrogen receptor"[Title/Abstract] OR 
"estrogen receptors"[Title/Abstract])))) OR (("Receptors, Progesterone"[Mesh]) OR 
(("progesterone receptors"[Title/Abstract] OR "progesterone receptor"[Title/Abstract])))) OR 
(("Receptors, Androgen"[Mesh]) OR (("androgen receptors"[Title/Abstract] OR "androgen 
receptor"[Title/Abstract])))) OR "Epidermal Growth Factor"[Mesh]) OR "human epidermal 
growth factor receptor-2"[Title/Abstract]) OR "HER2"[Title/Abstract]) OR 
"ERB2"[Title/Abstract]) OR "luminal A"[Title/Abstract]) OR "luminal B"[Title/Abstract]) OR 
(("HER-2"[Title/Abstract] OR "HER 2"[Title/Abstract]))) OR "basal-like"[Title/Abstract]))) OR 
(("Triple Negative Breast Neoplasms"[Mesh]) OR (((("Breast Neoplasms"[Mesh]) OR (("breast 
cancer"[Title/Abstract]) OR "breast neoplasms"[Title/Abstract]))) AND "triple 
negative"[Title/Abstract]))))) OR ((“estradiol receptor”[Title/Abstract] OR “estradiol 
receptors”[Title/Abstract]))) OR ((“Dihydrotestosterone Receptor”[Title/Abstract] OR 
“Dihydrotestosterone Receptors”[Title/Abstract] OR “Testosterone Receptor”[Title/Abstract] 
OR “Testosterone Receptors”[Title/Abstract]))) OR "Receptor, ErbB-2"[Mesh])) 
AND (((((“Case-Control Studies”[Mesh:noexp] OR "retrospective studies"[mesh:noexp] OR 
“Control Groups”[Mesh:noexp] OR (case[TIAB] AND control[TIAB]) OR (cases[TIAB] AND 
controls[TIAB]) OR (cases[TIAB] AND controlled[TIAB]) OR (case[TIAB] AND 
comparison*[TIAB]) OR (cases[TIAB] AND comparison*[TIAB]) OR “control group”[TIAB] 
OR “control groups”[TIAB])) OR (cohort studies[mesh:noexp] OR longitudinal 
studies[mesh:noexp] OR follow-up studies[mesh:noexp] OR prospective studies[mesh:noexp] 
OR retrospective studies[mesh:noexp] OR cohort[TIAB] OR longitudinal[TIAB] OR 
prospective[TIAB] OR retrospective[TIAB])) OR (Cross-Sectional Studies[Mesh:noexp] OR 
cross-sectional[TIAB] OR Prevalence[mesh:noexp] OR prevalence[tiab] OR transversal 
study[tiab])) OR ((systematic*[tiab] AND (bibliographic*[TIAB] OR literature[tiab] OR 
review[tiab] OR reviewed[tiab] OR reviews[tiab])) OR (comprehensive*[TIAB] AND 
(bibliographic*[TIAB] OR literature[tiab])) OR “cochrane database syst rev”[Journal] OR 
"Evidence report/technology assessment (Summary)"[journal] OR "Evidence report/technology 
assessment"[journal] OR "integrative literature review"[tiab] OR "integrative research 
review"[tiab] OR "integrative review"[tiab] OR “research synthesis”[tiab] OR “research 
integration”[tiab] OR cinahl[tiab] OR embase[tiab] OR medline[tiab] OR psyclit[tiab] OR 
(psycinfo[tiab] NOT “psycinfo database”[tiab]) OR pubmed[tiab] OR scopus[tiab] OR “web of 
science”[tiab] OR “data synthesis”[tiab] OR meta-analys*[tiab] OR meta-analyz*[tiab] OR 
meta-analyt*[tiab] OR metaanalys*[tiab] OR metaanalyz*[tiab] OR metaanalyt*[tiab] OR 
“meta-analysis as topic”[MeSH:noexp] OR Meta-Analysis[ptyp] OR ((review[tiab] AND 
(rationale[tiab] OR evidence[tiab])) AND review[pt]))) 
2.1 Study Eligibility: Inclusion criteria were studies concentrating on BC subtypes and 
reproductive factors as mentioned above. Exclusion criteria included studies not published in 
English, not published within January 1st, 2000 to December 31st, 2017, study outcomes other 
than BC subtypes, studies without researching reproductive factors, and studies with unavailable 
main estimates. 
2.2 Selection: A total of 7424 studies was retrieved from database searches, and 13 additional 
papers, including dissertation, were identified through other sources. Titles, abstracts, and full-
texts were reviewed by 2 authors for 6505 de-duplicated retrieved studies. 6379 studies were 
excluded through title review, which left 126 studies. Through abstract review, 105 studies were 
kept for the full-text review, which eventually gave 98 eligible studies. Articles were excluded 
for irrelevant studies and studies with critical missing data. 
2.3 Data extraction: Data was abstracted by one author. Each data entry was also independently 
reviewed and verified based on original full-texts by another author. Any discrepancies were 
discussed to reach consensus, and disagreements were resolved by consulting a third author. 
Specifically, author, year, study design (country of study, sample size, race, and data source, etc), 
BC subtypes (ER+PR+ BC, ER+PR- BC, ER-PR+ BC, ER-PR- BC, luminal A BC, luminal B 
BC, HER-2 overexpressing BC, and triple negative BC), reproductive factors, and corresponding 
estimates and their 95% confidence intervals were recorded. 
2.4 Statistical analysis: Odds ratios (OR), relative risks (RR), and hazard ratios (HR) for 
reproductive factors comparing the most extreme (e.g. highest vs. lowest) categories were 
extracted. To ensure consistency in meta-analysis, if needed, ratio measures were inverted to 
ensure reference categories matched across studies. Odds and hazard ratios were converted to 
approximate RR. When at least 3 studies of the exposure-outcome combination are available, a 
meta-analysis was separately conducted for each combination of exposure and each BC subtype 
defined by ERPR status. Included reproductive factors were: 1) age at menarche, 2) age at 
menopause, 3) menopause, 4) pregnancy, 5) age at first birth, 6) parity, 7) breastfeeding, 8) years 
since last birth, 9) oral contraceptive use, and 10) hormone replacement therapy. Random effects 
models were utilized to account for potential heterogeneity between the studies. Heterogeneity 
across studies was examined by I2-statistic18, 19, publication bias was assessed by Egger and 
Begg’s test 20, 21. All analyses were conducted using the STATA version 15 (Stata Corp LLC, 
College Station, TX). 
 
3. RESULTS 
Among all deduplicated 6505 studies searched from online database and review of reference 
lists, 98 studies were included according to the study inclusion and exclusion criteria (Figure 1). 
Among 98 studies, most of the eligible studies (64) were published between 2011 and 2017, 22 
studies were published from 2006 to 2010, and 12 studies were published between 2000 to 2005 
(Table 1). Data sources used in these studies include primary data (72), hospital databases (16), 
national cancer databases (5), and state registry data (5). However, study regions of five studies 
were unknown. Of these 98 studies, most studies were conducted in the United States (44), the 
other studies were conducted in Asia (19), Europe (16), multi-countries (9), Africa (3), Canada 
(1), and Australia (1). The 98 included studies investigated pregnancy/parity (64), breastfeeding 
(55), age at first birth (52), menarche/menstruation (48), OC use (28), hormone (27), menopausal 
status (22), age at menopause (21), and abortion (7). Among 98 eligible studies, 27 studies 
evaluated the association between reproductive factors and BC subtypes defined by ERPR 
status7-9, 15, 22-44. Characteristics of included studies are summarized in Table 1. Specifically, a 
total of 22 studies examined ER+PR+ BC subtype7-9, 22-28, 30-33, 35-41, 43, 14 studies examined 
ER+PR- BC subtype7-9, 22, 23, 27, 29, 30, 33, 38, 39, 41-43, 9 studies evaluated ER-PR+ BC subtype7, 8, 22, 23, 
27, 30, 39, 42, 43, and 25 studies evaluated ER-PR- BC subtype7-9, 15, 22-28, 30-39, 41-44. 
3.1 Age at menarche 
A total of 16 studies evaluated the association between age at menarche and BC subtypes defined 
by ERPR status7-9, 15, 22-28, 30, 31, 36, 37, 39. Among these, 15 studies researched ER+PR+ subtype7-9, 
22-28, 30, 31, 36, 37, 39, eight studies researched ER+PR- subtype7-9, 22, 23, 27, 30, 39, seven studies 
researched ER-PR+ subtype7, 8, 22, 23, 27, 30, 39, and 16 studies researched ER-PR- subtype7-9, 15, 22-28, 
30, 31, 36, 37, 39.  Of the 15 studies that contain ER+PR+ subtype, 10 studies found a statistically 
significant decreased likelihood of ER+PR+ subtype in women with late versus early age at 
menarche8, 9, 22, 23, 26, 27, 30, 31, 36, 37, while four studies found no statistically significant association7, 
24, 25, 39. Among these 15 studies, Huang et al and Cotterchio et al evaluated the association by 
menopausal status, Huang et al found the association was not statistically significant among both 
pre/peri and post-menopausal women30; however, Cotterchio et al found late age at menarche 
was only associated with ER+PR+ subtype compared with early age at menarche among 
premenopausal women28. A total of 8 studies researched the association between age at 
menarche and ER+PR- BC subtype7-9, 22, 23, 27, 30, 39, seven studies were not statistically 
significant7-9, 22, 23, 30, 39, while one study found late age at menarche was inversely associated 
with ER+PR- subtype27. A total of seven studies assessed the association between age at 
menarche and ER-PR+ BC, while all of them were not statistically significant7, 8, 22, 23, 27, 30, 39. Of 
16 studies that evaluated the association between age at menarche and ER-PR- BC subtype7-9, 15, 
22-28, 30, 31, 36, 37, 39, 10 studies found no significant association7, 9, 15, 23, 25, 28, 30, 36, 37, 39, four studies 
found late versus early age at menarche was associated with a decreased risk of ER-PR- 
subtype8, 22, 27, 31. Chung et al assessed the association by birth groups, although later age at 
menarche was only significantly associated with a reduced risk of ER-PR- subtype in women 
born in 1950s but not in 1940s and 1960s26. However, Cerne et al found later versus earlier age 
at menarche was associated with a higher likelihood of ER-PR- subtype24. 
In meta-analysis of 16 studies (Figure 2), late versus early age at menarche was associated with 
a statistically significant reduced risk of ER+PR+ BC subtype (RR:0.79, 95% CI: 0.72, 0.85, 
I2=87.9%, p=0.000), ER+PR- BC subtype (RR:0.75, 95% CI:0.58, 0.92, I2=37.3%, p=0.132), 
ER-PR+ BC subtype (RR: 0.79, 95% CI:0.63, 0.95, I2=0.0%, p=0.968), and ER-PR- BC subtype 
(RR:0.85, 95% CI: 0.79, 0.91, I2=59.1%, p=0.001). There is some evidence of publication bias 
(Egger’s: -2.09, p-value 0.042; Begg’s test: 1.71, p-value 0.087). 
3.2 Age at menopause 
A total of eight studies examined the association between age at menopause and BC subtypes 
based on ERPR status7, 9, 15, 22, 25, 27, 28, 37, seven studies analyzed ER+PR+ subtype7, 9, 22, 25, 27, 28, 37, 
four studies analyzed ER+PR- subtype7, 9, 22, 27, three studies analyzed ER-PR+ subtype7, 22, 27, 
and all eight studies analyzed ER-PR- subtype7, 9, 15, 22, 25, 27, 28, 37. Of seven studies analyzed 
ER+PR+ subtype7, 9, 22, 25, 27, 28, 37, three studies were not statistically significant7, 22, 37, while four 
studies found that late age at menopause was associated with an increased risk of ER+PR+ 
subtype9, 25, 27, 28. Of four studies evaluated the association between age at menopause and 
ER+PR- BC7, 9, 22, 27, three studies were not significant7, 9, 22, while one study observed that 
women with late versus early age at menopause were at a higher risk of getting ER+PR- 
subtype27. Of three studies evaluated the association between age at menopause and ER+PR- BC 
subtype7, 22, 27, only one study was significant27, which observed a higher risk of ER-PR+ subtype 
in women with later versus earlier age at menopause. Of eight studies assessed the association 
between age at menopause and ER-PR- BC subtype7, 9, 15, 22, 25, 27, 28, 37, seven studies were not 
significant7, 9, 15, 22, 25, 27, 37, while only one study found later age at menarche was associated with 
a higher risk of ER-PR- subtype28. 
In the meta-analysis of 8 studies (Figure 3.), late versus early age at menopause was associated 
with an increased risk of ER+PR+ BC (RR:1.30, 95% CI: 1.10, 1.50, I2=80.8%, p=0.000), 
ER+PR- BC (RR:1.52, 95% CI: 1.15, 1.90, I2=0.0%, p=0.937), ER-PR+ BC (RR:1.78, 95% 
CI:0.98, 2.57, I2=0.0%, p=0.938), and ER-PR- BC (RR:1.12, 95% CI: 1.00, 1.24, I2=31.9%, 
p=0.173). However, the association was only significant for ER+PR+ and ER+PR- subtype. 
There was evidence of publication bias (Egger’s: 6.28, p-value 0.000; Begg’s test: 0.34, p-value 
0.735). 
3.3 Menopausal status 
Among eight studies evaluated menopausal status and BC ERPR subtypes7, 8, 22, 23, 25, 29, 39, 42, six 
studies analyzed ER+PR+ subtype7, 8, 22, 23, 25, 39, seven studies analyzed ER+PR- subtype7, 8, 22, 23, 
29, 39, 42, six studies analyzed ER-PR+ subtype7, 8, 22, 23, 39, 42, and seven studies analyzed ER-PR- 
subtype7, 8, 22, 23, 25, 39, 42. Of six studies investigated the association between menopausal status 
and ER+PR+ BC subtype, five studies observed a significantly decreased likelihood of this 
subtype in women with post- versus pre/peri-menopause 7, 8, 22, 23, 25; another study observed that 
post- versus pre-menopause was significantly associated with an increased risk of ER+PR+ 
subtype39. Of seven studies evaluated the association between menopausal status and ER+PR- 
BC7, 8, 22, 23, 29, 39, 42, four studies observed no statistically significant associations7, 8, 22, 23, while 
two studies found that post- versus pre/peri-menopause was associated with a higher risk of 
ER+PR- subtype39, 42. Moreover, Fujisue et al found that among ER+PR- BC patients, the 
number of post-menopausal patients is 2.01 times of the number of pre-menopausal women29. Of 
six studies evaluated the association between menopausal status and ER-PR+ subtype7, 8, 22, 23, 39, 
42, five studies were not statistically significant7, 8, 23, 39, 42, while one study found that post-
menopause decreases the risk of ER-PR+ subtype compared to pre/peri-menopause22. Of seven 
studies assessed the association between menopausal status and ER-PR- subtype7, 8, 22, 23, 25, 39, 42, 
six studies were not statistically significant7, 8, 22, 23, 25, 39, only one study observed that post-
menopausal women were at a higher risk of this subtype compared to pre/peri-menopausal 
women42. 
In meta-analysis of eight studies (Figure 4), post- versus pre/peri-menopausal was associated 
with a statistically significant lower risk of ER+PR+ subtype (RR: 0.65, 95% CI: 0.55, 0.75, 
I2=45.1%, p=0.091) and ER-PR+ subtype (RR: 0.69, 95% CI: 0.51, 0.88, I2=24.1%, p=0.253), 
but a non-significant increased risk of  ER+PR- subtype (ES:1.16, 95% CI:0.76, 1.57, I2=62.6%, 
p=0.014) and ER-PR- subtype (RR:1.05, 95% CI: 0.88, 1.23, I2=46.2%, p=0.072) There was 
some evidence of publication bias (Egger’s: 2.21, p-value 0.036; Begg’s test: 1.72, p-value 
0.086). 
3.4 Pregnancy 
A total of six studies researched the association between pregnancy and BC ERPR subtypes8, 22, 
23, 26, 37, 43.  Specifically, all six studies analyzed ER+PR+ and ER-PR- subtype8, 22, 23, 26, 37, 43,  
four studies analyzed ER+PR- and ER-PR+ subtype8, 22, 23, 43. Of six studies analyzed the 
association between ER+PR+ subtype and pregnancy, four studies found ever pregnancy was 
significantly associated with a reduced risk of ER+PR+ BC22, 26, 37, 43, while other two studies 
were not statistically significant8, 23. Among four studies included ER+PR- BC, three studies 
were not statistically significant8, 22, 23, although one study observed a lower likelihood of 
ER+PR- BC in women with ever versus never pregnant or ever full-term versus never pregnant, 
but not in women with only non-full term versus never pregnant43. Of four studies evaluated ER-
PR+ subtype, three studies were not statistically significant8, 22, 23, while one study only observed 
a statistically significant lower risk of ER-PR+ BC subtype in women with only non-full-term 
pregnancy versus never pregnant43. Out of six studies examined the association between ER-PR- 
subtype and pregnancy, none of them was statistically significant8, 22, 23, 26, 37, 43. 
In the meta-analysis of six studies (Figure 5), ever versus never pregnancy was associated with a 
statistically reduced risk of ER+PR+ subtype (RR: 0.62, 95% CI: 0.47, 0.78, I2=88.0%, 
p=0.000), ER+PR- subtype (RR: 0.70, 95% CI: 0.57, 0.83, I2=0.0%, p=0.867), ER-PR+ subtype 
(RR: 0.68, 95% CI: 0.49, 0.87,  I2=3.5%, p=0.394), but a non-significant reduced risk of ER-PR- 
subtype (RR:0.97 , 95% CI: 0.86, 1.07, I2=0.0%, p=0.718) There was no evidence of publication 
bias (Egger’s: 0.54, p-value 0.593; Begg’s test: 1.09, p-value 0.277). 
3.5 Age at first birth 
A total of 16 studies evaluated the association between age at first birth and BC subtypes defined 
by ERPR status7-9, 15, 22-24, 26-28, 30, 31, 33, 37, 39, 43, 15 studies analyzed ER+PR+ BC subtype7-9, 22-24, 
26-28, 30, 31, 33, 37, 39, 43; 10 studies analyzed ER+PR- BC subtype7-9, 22-24, 27, 30, 33, 39, eight studies 
analyzed ER-PR+ BC subtype7, 8, 22-24, 27, 30, 39, and 16 studies analyzed ER-PR- BC subtype7-9, 15, 
22-24, 26-28, 30, 31, 33, 37, 39, 43. 
ER+PR+ BC: A total of 15 studies evaluated the association between nulliparity and age at first 
birth with ER+PR+ subtype7-9, 22-24, 26-28, 30, 31, 33, 37, 39, 43; six studies examined nulliparity versus 
age at first birth9, 24, 27, 28, 30, 39, while 13 studies examined late age at first birth versus early age at 
first birth7-9, 22, 23, 26, 28, 30, 31, 33, 37, 39, 43. Among the six studies that evaluated the association 
between nulliparity versus age at first birth and ER+PR+ subtype9, 24, 27, 28, 30, 39, four studies 
evaluated nulliparity versus early age at first birth9, 28, 30, 39. Among these four studies, two 
studies found no statistically significant association30, 39, while two studies observed that 
nulliparity versus earlier age at first birth was associated with an increased risk of ER+PR+ 
subtype9, 28. Two studies evaluated this association by menopausal status28, 30; Huang et al did not 
observe any significant associations overall or by subtypes30, while Cotterchio observed a 
significantly increased risk in both pre- and post-menopausal women28. Two studies evaluated 
the association between nulliparity versus later age at first birth, while none of them was 
statistically significant24, 27. A total of 13 studies evaluated the association between late versus 
early age at first birth and ER+PR+ BC subtype7-9, 22, 23, 26, 28, 30, 31, 33, 37, 39, 43; four studies 
observed a significantly increased risk of ER+PR+ subtype7-9, 37, while seven studies were not 
significant22, 23, 30, 31, 33, 39, 43. Two studies evaluated the association by menopausal status28, 30; 
Huang et al did not observe any significant associations in pre- or post-menopausal women30, 
while Cotterchio observed significantly increased risk only in post-menopausal women28. Chung 
et al evaluated the association by birth cohorts and found significant positive associations for the 
1950 and 1960 cohort, but not 194026. 
ER+PR- BC: A total of 10 studies focused on the ER+PR- BC subtype7-9, 22, 23, 27, 30, 33, 39, 43, three 
studies examined the association between nulliparity versus early age at first birth, but found no 
statistically significant results9, 30, 39. One study compared nulliparity to late age at first birth, but 
still found no statistically significant association27. Of the nine studies7-9, 22, 23, 30, 33, 39, 43 that 
compared late versus early age at first birth, three studies observed a significantly increased 
likelihood of ER+PR- BC subtype7, 9, 39, while the other studies were not statistically significant8, 
22, 23, 30, 33, 43. 
ER-PR+ BC: A total of eight studies evaluated the association between age at first birth and ER-
PR+ BC subtype7, 8, 22, 23, 27, 30, 39, 43, three studies evaluated nulliparity versus age at first birth, 
with two studies30, 39 compared nulliparity to earlier age at first birth and one studies27 compared 
nulliparity to later age at first birth. All these three studies found no statistically significant 
results. Of the seven studies7, 8, 22, 23, 30, 39, 43 that assessed late versus early age at first birth, only 
one study observed that a statistically significant increased risk was associated with late age at 
first birth8, while the other studies were not statistically significant7, 22, 23, 30, 39, 43 . 
ER-PR- BC: A total of 16 studies evaluated the ER-PR- BC subtype7-9, 15, 22-24, 26-28, 30, 31, 33, 37, 39, 
43,  4 studies assessed nulliparity versus early age at first birth9, 28, 30, 39, 2 studies assessed 
nulliparity versus late age at first birth24, 27, and none were statistically significant, while 14 
studies examined late versus early age at first birth and also found no statistically significant 
results7-9, 15, 22, 23, 26, 28, 30, 31, 33, 37, 39, 43. 
In meta-analysis of the studies that evaluated age at first birth in relation to BC subtypes  
(Figure 6), nulliparity compared with age at first birth was associated with a statistically 
significant increased risk of ER+PR+ BC subtype (RR: 1.27, 95% CI: 1.01, 1.54, I2=50.5%, 
p=0.059), a statistically significant reduced risk of ER+PR- BC subtype (RR: 0.71, 95% CI: 
0.46, 0.96, I2=0.0%, p=0.44), and a non-significant but reduced risk of ER-PR+ subtype (RR: 
0.68, 95% CI: 0.26, 1.11, I2=0.0%, p=0.663) and ER-PR- subtype (RR: 0.91, 95% CI: 0.71, 1.10 
I2=0.0%, p=0.488) subtypes. Late age at first birth compared with early age at first birth was 
associated with statistically increased risk of ER+PR+ subtype (RR: 1.10, 95% CI: 1.04, 1.15, 
I2=63.2%, p=0.000) and ER+PR- subtype (RR: 1.45, 95% CI: 1.15, 1.74, I2=0.0%, p=0.767) , but 
non-significant for ER-PR+ subtype (RR: 1.03, 95% CI: 0.72, 1.33, I2=5.7%, p=0.384) and ER-
PR- subtype (RR: 0.99, 95% CI: 0.97, 1.01 I2=0.0%, p=0.476) subtypes. There was some 
evidence of publication bias (Egger’s: 2.27, p-value 0.027; Begg’s test: 0.97, p-value 0.333). 
3.6 Parity 
There are 16 studies in total researched the associations between parity and BC subtypes based 
on ERPR status7-9, 15, 22, 24-26, 28, 31-33, 37, 42-44. Specifically 13 studies assessed ER+PR+7-9, 22, 24-26, 28, 
31, 33, 37, 43, 44, seven studies assessed ER+PR- BC7-9, 22, 33, 42, 43, five studies assessed ER-PR+ BC7, 
8, 22, 42, 43, and 16 studies assessed ER-PR- BC7-9, 15, 22, 24-26, 28, 31-33, 37, 42-44 
ER+PR+ BC: A total of 13 studies examined the association between parity and ER+PR+ BC 
subtype. A total of eight studies evaluated larger parity versus nulliparous7, 24, 25, 28, 31, 33, 43, 44, and 
five studies evaluated large parity versus small parity8, 9, 22, 26, 37. Among eight studies 
investigated larger parity versus nulliparity,  five studies found that larger parity was 
significantly associated with a reduced risk of ER+PR+ subtype7, 28, 31, 43, 44, while one study 
found no statistically significant association24. Moreover, Chen et al and Palmer et al examined 
by age-group, Chen et al found larger parity reduced the risk of ER+PR+ in women <=22 years 
and 23-25 years groups but not in >25 years group25, Palmer et al found that the same 
association, which was significant overall and in women >=45 years but not in women<45 
years33. Among five studies evaluated the association between large versus small parity and 
ER+PR+ subtype8, 9, 22, 26, 37, three of them were not significant8, 22, 26, while two studies found a 
reduced risk for ER+PR+ subtype with large versus small parity9, 37. 
ER+PR- BC: A total of seven studies evaluated the association between parity and ER+PR- BC 
subtype7-9, 22, 33, 42, 43, four evaluated larger parity versus nulliparity7, 33, 42, 43. Among these, three 
studies were not statistically significant7, 33, 42, while one study found that women with larger 
parity has a reduced risk of ER+PR- subtype compared to nulliparous women43. A total of four 
studies evaluated large versus small parity, three studies found no statistically significant 
association8, 9, 22, while one study observed larger parity was in relation to a statistically 
significant increased risk of ER-PR- subtype42. 
ER-PR+ BC: A total of five studies evaluated the association between parity and ER-PR+ BC 
subtype7, 8, 22, 42, 43, three studies examined large parity versus nulliparity, but no study was 
statistically significant7, 42, 43. three studies examined the association between large versus small 
parity and ER-PR+ subtype but found no statistically results8, 22, 42. 
ER-PR- BC: A total of 16 studies analyzed the association between parity and ER-PR- BC 
subtype7-9, 15, 22, 24-26, 28, 31-33, 37, 42-44, with 11 studies examined large parity versus nulliparity7, 15, 24, 
25, 28, 31-33, 42-44 and six studies evaluated larger versus smaller parity8, 9, 22, 26, 37, 42.  Out of 11 
studies that evaluated large parity versus nulliparity, nine studies found no statistically 
significant results7, 15, 24, 25, 28, 31, 33, 42, 43. Palmer et al and Work et al evaluated parity combined 
with breastfeeding status, Palmer et al found that larger parity without breastfeeding versus 
nulliparity posts a statistically significant increased risk for ER-PR- subtype32, but not for large 
parity with breastfeeding. Differently, Work et al found the opposite result44. Out of six studies 
that evaluated larger versus smaller parity8, 9, 22, 26, 37, 42, four studies were not statistically 
significant8, 9, 26, 37; however, one study found larger parity was associated with a higher risk of 
ER-PR- subtype42, but one study observed that larger parity was associated with a lower risk of 
ER-PR- subtype22. 
In the meta-analysis that evaluated the association between parity and ERPR BC subtypes 
(Figure 7), large parity versus nulliparity was associated with a statistically reduced risk of 
ER+PR+ subtype (RR: 0.67, 95% CI: 0.56, 0.78, I2=75.4%, p=0.000), ER+PR- subtype (RR: 
0.54, 95% CI: 0.30, 0.78, I2=23.5%, p=0.270), a reduced but not statistically significant risk of 
ER-PR+ subtype (RR: 0.71, 95% CI: 0.33, 1.08, I2=0.0%, p=0.515) and ER-PR- subtype (
RR: 0.96, 95% CI: 0.84, 1.08, I2=34.2%, p=0.089). Larger versus smaller parity was associated 
with a statistically significant reduced risk for ER+PR+ subtype (RR: 0.88, 95% CI: 0.77, 0.99, 
I2=69.3%, p=0.003), but a statistically increased risk for ER+PR-(RR: 1.08, 95% CI: 0.76, 1.40, 
I2=33.9%, p=0.209), and a non-significant reduced risk for ER-PR+ subtype (RR: 096, 95% 
CI: 0.74, 1.18, I2=0.0%, p=0.597), and ER-PR- subtype (RR: 0.96, 95% CI: 0.83, 1.10, 
I2=61.6%, p=0.011). There is no evidence of publication bias (Egger’s: 1.64, p-value 0.107; 
Begg’s test: 0.90, p-value 0.371). 
3.7 Breastfeeding 
There are 13 studies examined the association between breastfeeding and BC subtypes defined 
by ERPR status8, 15, 22-24, 26, 28, 30, 31, 33, 37, 39, 43. Among all, 12 studies analyzed ER+PR+8, 22-24, 26, 28, 
30, 31, 33, 37, 39, 43, seven studies assessed ER+PR- subtype8, 22, 23, 30, 33, 39, 43, six studies analyzed ER-
PR+ subtype8, 22, 23, 30, 39, 43, and all 13 studies investigated ER-PR- BC8, 15, 22-24, 26, 28, 30, 31, 33, 37, 39, 
43. 
ER+PR+ BC: Of 12 studies included ER+PR+ BC8, 22-24, 26, 28, 30, 31, 33, 37, 39, 43, six studies 
evaluated the association between ever versus never breastfeeding and this subtype8, 26, 30, 32, 37, 43; 
and 11 studies evaluated duration of breastfeeding 8, 22-24, 26, 28, 31, 33, 37, 39, 43. Of six studies 
evaluated the association between ever versus never breastfeeding and ER+PR+ subtype, five 
studies were not statistically significant8, 26, 30, 33, 37, while one observed that ever breastfeeding is 
inversely associated with ER+PR+ subtype43. Of 11 studies evaluated the association between 
breastfeeding duration and ER+PR+ subtype, seven studies found non-significant association23, 
24, 26, 28, 33, 37, 39, whilst 4 studies showed longer duration of breastfeeding is inversely associated 
with ER+PR+ BC8, 22, 31, 43. 
ER+PR- BC: Of seven studies assessed the association between breastfeeding and ER+PR-BC8, 
22, 23, 30, 33, 39, 43, three studies assessed ever versus never breastfeeding in relation to ER+PR- 
subtype 8, 30, 43, with only one study observed breastfeeding was associated with a statistically 
significant reduced risk of ER+PR- subtype30. A total of six studies examined the duration of 
breastfeeding8, 22, 23, 33, 39, 43, with only one study found breastfeeding longer than one year lowers 
the risk of ER+PR- BC23. 
ER-PR+ BC: There were six studies evaluated the association between breastfeeding and ER-
PR+ subtype8, 22, 23, 30, 39, 43. A total of three studies assessed ever versus never breastfeeding8, 30, 
43, although only one study found that ever breastfeeding was associated with a statistically 
significant reduced risk of ER-PR+ subtype30.  All six studies assessed breastfeeding duraiton8, 22, 
23, 33, 39, 43, while only one study found, comparing to shorter duration of breastfeeding, longer 
duration was associated with a lower likelihood of ER-PR+ subtype8. 
ER-PR- BC: Of 13 studies investigated the association between breastfeeding and ER-PR- BC 
subtype8, 15, 22-24, 26, 28, 30, 31, 33, 37, 39, 43, seven studies examined ever versus never breastfeeding8, 15, 
26, 30, 33, 37, 43. Of these, four studies were not significant8, 30, 33, 35, while two studies observed ever 
breastfeeding had a lower likelihood of ER-PR- subtype15, 43. Additionally, Chung et al evaluated 
by birth-cohort, and results were not consistent across birth conhorts26. Out of 13 total studies, 11 
studies assessed duration of breastfeeding8, 22-24, 26, 28, 31, 33, 37, 39, 43. Of these, 10 studies were not 
statistically significant, while only one study found that longer duration of breastfeeding was 
associated with a reduced risk of ER-PR- BC43. 
In the meta-analysis that evaluated the association between breastfeeding and BC ERPR 
subtypes (Figure 8), ever versus never breastfeeding was associated with a statistically 
significant reduced risk of ER+PR+ subtype (RR: 0.87, 95% CI: 0.79, 0.96, I2=46.0%, p=0.054), 
ER+PR- subtype (RR: 0.67, 95% CI: 0.52, 0.83, I2=18.2%, p=0.300), and ER-PR- subtype (RR: 
0.81, 95% CI: 0.69, 0.93, I2= 60.9%, p=0.004), but a non-significant reduced risk for ER-PR+ 
subtype ((RR:0.67, 95% CI: 0.27, 1.08, I2=46.0%, p=0.136). Longer versus shorter duration of 
breastfeeding was in relation to a non-significant reduced risk for ER+PR+ subtype (RR: 0.99, 
95% CI: 0.97, 1.01, I2=72.0%, p=0.000) and ER-PR+ subtype (RR:0.67 , 95% CI: 0.26, 1.08, 
I2=48.2%, p=0.102), but a statistically reduced risk of ER+PR- subtype (RR: 0.67, 95% CI: 0.40, 
0.94, I2=52.0%, p=0.064), and no difference for ER-PR- subtype (RR: 1.00, 95% CI: 0.98, 1.01, 
I2=60.6%, p=0.002). There is evidence of publication bias (Egger’s: -5.96, p-value 0.000; Begg’s 
test: 3.45, p-value 0.001). 
3.8 Years since last birth 
A total of three studies evaluated the association between years since last birth and ER+PR+ 
BC33, 37, 43, two studies found that shorter year since last birth was significantly associated with a 
higher risk of this subtype33, 37. Among these two studies, Palmer et al also evaluated the 
association by age-group (<45 years, >=45 years), although it was not statistically significant33. 
Another study found shorter year since last birth was inversely associated with ER+PR+BC 
subtype43. A total of 3 studied focused on ER-PR- BC stubtype33, 37, 43, 2 studies were not 
significant37, 43, while Palmer only found a statistically significant increased risk of ER-PR- BC 
in women <45 years but not in overall and >=45 years with shorter versus longer since last 
birth33. 
In the meta-analysis of three studies that assessed the association between years since last birth 
and BC ERPR subtypes (Figure 9), shorter versus longer years since last birth was in relation to 
a non-significant increased risk of ER+PR+ subtype (RR:1.05, 95% CI:0.53, 1.57, I2=88.1%, 
p=0.000) and ER-PR- subtype (RR:1.02, 95% CI:0.81, 1.24, I2=12.9%, p=0.317). There is no 
evidence of publication bias (Egger’s: -0.11, p-value 0.919; Begg’s test: 0.000, p-value 1.000). 
3.9 Oral contraceptive (OC) use 
Among 10 studies that analyzed OC use, all included ER+PR+ and ER-PR- BC8, 22-24, 28, 30, 31, 37, 
38, 44, five studies included ER+PR-8, 22, 23, 30, 38, and three studies included ER-PR+BC22, 23, 30. 
ER+PR+ BC: A total of 10 studies evaluated the association between OC use and ER+PR+ BC 
subtypes8, 22-24, 28, 30, 31, 37, 38, 44, six studies evaluated ever OC use versus never8, 22, 23, 30, 38, 44, one 
evaluated current or past OC  use versus never37, and six studies evaluated OC duration, none of 
these six studies was statistically significant22, 24, 28, 31, 37, 38. Of six studies examined ever OC use 
versus never8, 22, 23, 30, 38, 44, five studies were not statistically significant8, 22, 23, 30, 38, while one 
study observed ever used OC was significantly associated with a lower likelihood of ER+PR+ 
subtype44. The study that assessed the association between current or past versus never OC use 
was not significant as well37. 
ER+PR- BC: A total of five studies evaluated the association between OC use and ER+PR- BC8, 
22, 23, 30, 38, all five studies examined the association between ever versus never OC use and 
ER+PR- subtype and two examined the association between OC use duration and ER+PR- 
subtype22, 38, although all of them were not statistically significant. 
ER-PR+ BC: A total of three studies evaluated the association between OC use and ER-PR+ BC 
subtype22, 23, 30, all three evaluated ever versus never OC use, and one evaluated OC use 
duraiton22; however, none of them was statistically significant. 
ER-PR- BC: A total of 10 studies evaluated the association between OC use and ER-PR- BC8, 22-
24, 28, 30, 31, 37, 38, 44, 5 studies evaluated ever OC use versus never8, 22, 23, 30, 38, one study evaluated 
OC use prior 1975 versus no44, one study evaluated current or past OC use versus never37, and 
six studies OC duraiton22, 24, 28, 31, 37, 38. Of 5 examined ever OC use vs never8, 22, 23, 30, 38, four 
studies were not statistically significant8, 22, 23, 30, while one study found ever OC use versus never 
had a higher risk of ER-PR- subtype38. Among six studies assessed OC duration22, 24, 28, 31, 37, 38, 
five of them were not statistically significant22, 24, 28, 31, 37, while one study found that longer 
duration of OC use increases the risk of ER-PR- subtype38. 
In the Meta-analysis that evaluated the association between OC use and BC ERPR subtypes 
(Figure 10), ever versus never OC use was associated with a non-significant reduced risk of 
ER+PR+ subtype (RR: 0.96, 95% CI: 0.81, 1.10, I2=81.6%, p=0.000), a non-significant 
increased risk of ER+PR- subtype (RR:1.09 , 95% CI: 0.86, 1.32, I2=0.0%, p=0.901) and ER-
PR+ subtype(RR: 1.09, 95% CI: 0.53, 1.66, I2=31.5%, p=0.232), a significant increased risk of 
ER-PR- subtype (RR: 1.17, 95% CI: 1.02, 1.31, I2=29.3%, p=0.194). Longer versus shorter 
duration of OC use was associated with a non-significant reduced risk of ER+PR+ subtype (RR: 
0.92, 95% CI: 0.81, 1.04, I2=19.9%, p=0.272) and a non-significant increased risk of ER-PR- 
subtype (RR: 1.20, 95% CI: 1.00, 1.41, I2=14.1%, p=0.320). There is evidence of publication 
bias (Egger’s: 3.67, p-value 0.001; Begg’s test: 2.13, p-value 0.003). 
 
3.10 Hormone replacement therapy 
A total of 13 studies assessed the association between hormone replacement and BC subtypes, 13 
studies analyzed ER+PR+ subtype7-9, 22, 24, 25, 27, 28, 30, 35, 39-41, eight studies analyzed ER+PR- 
subtype7-9, 22, 27, 30, 39, 41, six studies analyzed ER-PR+ subtype7, 8, 22, 27, 30, 39, and 12 studies 
analyzed ER-PR- subtype7-9, 22, 24, 25, 27, 28, 30, 35, 39, 41 
ER+PR+ BC: A total of 13 studies focused on the association between hormone replacement 
therapy and ER+PR+ BC subtypes7-9, 22, 24, 25, 27, 30, 35, 39-41, 12 studies evaluated hormone 
replacement therapy (ever, past or current) versus never use7-9, 22, 24, 25, 27, 30, 37, 39-41, and five 
studies evaluated hormone replacement therapy duration7, 24, 25, 28, 41. Among 12 studies that 
evaluated the association of hormone replacement with ER+PR+ subtype, seven studies found 
non-significant associations7, 8, 22, 25, 30, 39, 41, while two studies observed a statistically significant 
higher risk associated with hormone replacement therapy9, 40. However, Colditz et al only found 
this association for estrogen and progesterone use but not for estrogen use only27. In contrast to 
Colditz’s finding, Cerne et al found a statistically significant reduced risk for estrogen only, and 
non-significant results for combined hormones24. Ritte et al evaluated the association by BMI 
and found significant associations across all BMI groups among current users, but not among 
past users35. A total of five studies7, 24, 25, 28, 41 evaluated the association of hormone replacement 
therapy duration and ER+PR+ BC subtype, two studies found no statistically significant 
association7, 28, whilst two studies observed that longer duration of hormone replacement therapy 
was significantly associated with a higher risk of ER+PR+ subtype25, 41, and one study found 
longer duration of hormone replacement therapy was inversely associated with this subtype24. 
ER+PR- BC: A total of eight studies investigated the association between hormone replacement 
and ER+PR- BC subtype7-9, 22, 27, 30, 39, 41, all eight studies examined ever versus never hormone 
use. Of these, five studies found no statistically significant associations7, 8, 27, 39, 41, while one 
study found ever receiving hormone replacement therapy versus never was statistically 
associated with a reduced risk of ER+PR- subtype30, and two studies found ever receiving 
hormone replacement therapy versus never was associated with an increased risk of ER+PR- 
subtype9, 22, although Setiawan only observed the significant association for current hormone 
replacement therapy versus never but not for past hormone replacement therapy versus never9. A 
total of two studies evaluated the association between hormone replacement therapy duration and 
ER+PR- subtype, none of them was significant7, 9 
ER-PR+ BC: A total of six studies evaluated the association between hormone replacement 
therapy and ER-PR+ BC subtype7, 8, 22, 27, 30, 39. All these six studies evaluated ever receiving 
hormone replacement therapy versus never, while none of them was significant. There was only 
one study examined longer versus shorter duration of hormone replacement, and it was not 
statistically significant7. 
ER-PR- BC: A total of 12 studies assessed the association between hormone use and ER-PR- 
BC subtype7-9, 22, 24, 25, 27, 28, 30, 35, 39, 41, with 11 studies assessed ever receiving hormone 
replacement therapy versus never7-9, 22, 24, 25, 27, 30, 35, 39, 41, and five studies assessed duration of 
hormone replacement therapy7, 24, 25, 28, 41. Of 11 studies evaluated ever receiving hormone 
replacement therapy versus never, eight studies were not statistically significant7-9, 22, 24, 27, 39, 41, 
while one study found past hormone replacement therapy was associated with a lower risk of 
ER-PR- subtype25. Huang et al evaluated the association by menopausal status30, and Ritte et al 
evaluated by BMI-group35. However, Huang et al only detected ever versus never hormone 
replacement therapy was inversely associated with ER-PR- subtype in peri- and post-menopausal 
women30; Ritter et al only observed that current hormone replacement therapy versus never use 
was associated with a higher risk of ER-PR- subtype among women with BMI <=22.535. A total 
of five studies evaluated the association between duration of hormone replacement therapy and 
ER-PR- subtype, although all of them were not significant7, 24, 25, 28, 41. 
In the meta-analysis of the association between hormone replacement therapy and BC ERPR 
subtypes (Figure 11), ever versus never receiving hormone replacement therapy was associated 
with a statistically significant increased risk of ER+PR+ subtype (RR:1.25 , 95% CI: 1.08, 1.42, 
I2=83.4%, p=0.000) a non-significant increased risk of ER+PR- subtype (RR: 1.10, 95% CI: 
0.78, 1.42, I2=75.3%, p=0.000), a non-significant reduced risk for ER-PR- subtype (RR: 0.98, 
95% CI: 0.86, 1.10, I2=35.8%, p=0.053), but no difference for ER-PR+ subtype (RR:1.00 , 95% 
CI: 0.71, 1.30, I2=0.0%, p=0.746). Longer versus shorter duration of hormone replacement 
therapy was in relation to a statistically increase likelihood of ER+PR+ subtype (RR: 1.39, 95% 
CI: 1.02, 1.76, I2=86.2%, p=0.000), but a non-significant increased likelihood of ER-PR- subtype 
(RR: 1.01, 95% CI: 0.82, 1.20, I2=0.0%, p=0.429). There is some evidence of publication bias 
(Egger’s: 1.63, p-value 0.107; Begg’s test: 1.99, p-value 0.047). 
3.11 Summary of the meta-analysis 
Out of ten reproductive factors included in the meta-analysis, the effect of age at menarche was 
consistent across subtypes, and the strongest association was observed in ER+PR- subtype. 
Moreover, the impact of pregnancy and ever breastfeeding was relatively less consistent (Table 
2), and the strongest association for these two factors were respectively for ER-PR+ and ER+PR- 
subtypes. In addition, nulliparity versus early at first birth has conflicting results across ER+PR+ 
and ER+PR- subtypes. What is more, larger versus smaller parity only showed a statistically 
significant reduced risk for ER+PR+, and HRT only associated with a higher risk for ER+PR+.  
Larger versus smaller duration of breastfeeding was only associated with a reduced risk for 
ER+PR- subtype. Years since last birth and OC use were not statistically significant. Age at 
menopause, menopausal status, late versus early age at first birth, and larger parity versus 
nulliparity was associated with differently two subtypes. Considering the magnitude of these 
association overall, six out of 13 comparison groups has the strongest associations with ER+PR-, 
and two strongest association were observed for ER+PR+ subtype. 
 
4. DISCUSSION 
This study reviewed 98 eligible studies for all subtypes and the meta-analysis included 27 studies 
about the association between reproductive factors and BC subtypes defined by ERPR status. It 
has been reported that BC is a heterogeneous cancer with different distributions of reproductive 
factors; however, no meta-analysis is available for ER+PR+ and ER-PR+ subtypes. Additionally, 
currently available systematic reviews and meta-analyses solely evaluated a few reproductive 
factors3, 5, 14-16, 45. However, this study summarized and assessed the association between ERPR 
subtypes and ten reproductive factors (age at menarche, age at menopause, menopausal status, 
pregnancy, age at first birth, parity, breastfeeding, years since last birth, OC use, and HRT). To 
our knowledge, this meta-analysis is the first study that investigated the association between joint 
ERPR subtypes (ER+PR- and ER-PR+) and reproductive factors. For ER+PR+ and ER-PR- 
subtypes, this meta-analysis also firstly evaluated menopausal status, years since last birth, OC 
use, and HRT. 
Similar to other findings3, 4, 14, 15, BC is heterogeneous and reproductive factors patterns vary by 
subtypes. Moreover, this meta-analysis found that consistency of associations across subtypes 
differs by risk factors (Table 2). Specifically, late age at menarche was protective for all four 
ERPR subtypes. Ever pregnancy was observed to be protective for ER+PR+, ER+PR-, and ER-
PR+ subtypes. Breastfeeding reduces the risk of ER+PR+, ER+PR-, and ER-PR- subtypes. 
Additionally, the effects of age at menopause, menopausal status, age at first birth, parity, 
breastfeeding duration, and HRT are believed to be relatively less consistent across ERPR 
subtypes. No significant results were found for OC use and years since last birth. Generally, most 
significant associations were found for ER+PR+ and/or ER+PR- subtype (Age at menopause, 
age at first birth, parity, and HRT). Differently, late versus early age at menarche was associated 
with a reduced risk for all subtypes. Post- versus pre-menopause were associated with PR+ BC 
(ER+PR+ and ER-PR+ subtypes). Most of our strongest association was observed for ER+PR- 
subtype, which broadens studies which only investigated ER+PR+ and ER-PR- subtypes16. It 
also expands the result from another finding that hormone receptor positive BC had the strongest 
strength3. 
Factors that have been evaluated in meta-analyses include age at menarche, age at menopause, 
parity, age at first birth, and breastfeeding. However, in this meta-analysis, more recent studies 
were included and additional reproductive factors (menopausal status, years since last birth, OC, 
use, and HRT) were examined through a meta-analysis. A few systematic reviews found most 
studies observed an inverse association between age at menarche and ER+PR+ subtype3, 5, 16. The 
systematic review from Ma et al found ER+PR+ subtype has a stronger association compared to 
ER-PR-16. However, our meta-analysis found late age at menarche reduced the risk of all four 
ERPR subtypes. The association was strongest for ER+PR- subtype and was weakest for ER-PR- 
subtype in this analysis. However, among eight studies included in the meta-analysis for ER+PR- 
subtype, only one study conducted by Colditz observed a statistically significant lower risk with 
a narrow confidence interval27. For age at menopause, a meta-analysis conducted by Li et al 
found an increased risk in luminal subtype (defined as ER+ or PR+, HER2+ or HER2-) and ER-
PR- subtypes15, while our meta-analysis found late age at menopause increases the risk of 
ER+PR+ and ER+PR- subtypes. Different results might be due to more recent studies included in 
our study. For age at first birth, the meta-analysis conducted by Ma et al found late versus early 
age at first birth was only associated with ER+PR+ subtype but not ER-PR- subtype16. However, 
another meta-analysis found it was associated with an insignificant increased risk for luminal BC 
but a reduced risk for ER-PR-15 and our meta-analysis found a statistically significant increased 
risk for ER+PR+ and a reduced risk for ER-PR- subtype. Additionally, our study also observed 
that nulliparity versus age at first birth was associated with a higher risk for ER+PR+ but a lower 
risk for ER+PR- subtype. Regarding pregnancy, a meta-analysis found ever pregnant was 
associated with a reduced risk only for luminal BC4, while ever pregnant was associated with a 
reduced risk for all subtypes except for ER-PR- subtype, and the strongest association is 
observed for ER+PR+ subtype in our study. For parity, which is defined as the number of 
children a women gave birth to, Li et al observed that nulliparity was associated with a higher 
risk for luminal subtype compared to larger parity15, and Ma et al only found highest versus 
lowest parity reduces the risk for ER+PR+ subtype16. Similarly, our study found large parity 
versus nulliparity was associated with a reduced risk for both ER+PR+ and ER+PR- subtype. We 
also observed that larger versus smaller parity was only associated with a 12% reduced risk of 
ER+PR+ subtype. In addition. As the finding by Isiami et al14 for ever breastfeeding, a reduced 
risk was observed for ER+PR+ and ER-PR-; however, our meta-analysis also found a 
statistically significant lower risk for ER-PR+ subtypes. Moreover, the association was stronger 
for ER-PR- compared to ER+PR+ subtype, and it was strongest for ER+PR- subtype. No meta-
analysis evaluated the association between BC ERPR subtypes and breastfeeding duration, while 
our study found large versus small duration of breastfeeding was also protective for all four 
subtypes except for ER-PR- subtype, although it was only statistically significant for ER+PR- 
subtype. No significant association was observed for years since last birth and OC use. 
Additionally, the impact of OC varies by subtypes with only Work et al44 found a statistically 
significant reduced likelihood for ER+PR+ subtype. For ER-PR- subtype, only Rosernberg et 
al38 and Work et al44 found a statistically significant increased risk. Further studies are required 
for a deeper assessment for the impact of OC use by subtypes. A 35% reduced risk and a 31% 
reduced risk were separately observed for ER+PR+ and ER-PR+ subtype with post- versus pre-
/perimenopause, which reflects previous findings7, 8, 22, 23, 25 and differs from Rusiecki’s finding39. 
For HRT, ever received HRT and long versus short duration of HRT were only associated with a 
higher risk of ER+PR+ subtype, which confirms previous findings9, 25, 43, although it contrasts 
with some other findings24, 30, 39. 
Age at menopause, age at first birth, and parity were significantly associated with ER+ (ER+PR+ 
and ER+PR- subtypes) in our meta-analysis. HRT was only associated with ER+PR+ subtypes. 
These factors might work through the effect of estrogen and/or progesterone8. For instance, later 
age at menarche leads to a shorter duration of hormone exposure, which is probably associated 
with a lower risk of all ER+BC37. For factors that were significantly associated with ER+ BC, 
estrogen circulating level might be impacted by those factors and thus changes the risk of ER+ 
BC45. Evidence has shown that pregnancy probably reduces risk through hormone circulating 
level change and breast structure change from undifferentiated to differentiated breast epithelial 
cells46, 47. Breastfeeding is also believed to be associated with breast structure changes.47 For 
menopausal status, pre-menopausal women were believed to have a higher level of steroid and 
thus are more likely to develop PR+ subtype in pre-menopausal status and to develop PR- in 
post-menopausal status42. 
There are a few gaps, for studies focusing on the association between reproductive factors and 
ERPR subtypes, should be addressed. To begin with, abortion was not included in the meta-
analysis due to insufficient studies of this factor. Moreover, no significant association was 
observed for years since last birth and OC use. These suggest that more studies should focus on 
abortion, years since last birth, and OC use. What is more, definitions of these reproductive 
factors vary by studies, which might cause misclassification of these factors. For instance, most 
studies refer parity as number of children7, 28, 44; however, some studies refer it as ever pregnant4, 
23. Clear definitions would help reduce the confusions and misclassification of these reproductive 
factors. Moreover, risk patterns of BC were believed to be different by menopausal status48. 
However, a meta-analysis, stratifying by menopausal status for any association between 
reproductive factors and BC ERPR subtypes, was not conducted due to insufficient primary 
studies. Primary studies researching the association stratified by menopausal status could help 
better understand these associations in pre/peri- and postmenopausal women. 
This study has its own limitations. To begin with, our eligible studies were restricted to papers 
published in English, which reduces the comprehensiveness of this study. However, we included 
98 studies that investigated these associations and were published in the most commonly used 
language. Moreover, not enough studies were available to conduct a meta-analysis for abortion, 
and only three studies examined years since last birth. Thus, more studies are needed to be done 
to address gaps in these factors. However, except for these two factors, we still assessed the 
association between other eight factors and BC ERPR subtypes. Moreover, different etiologies of 
pre-menopausal and post-menopausal BC have been reported42. However, not enough studies 
were available for a meta-analysis stratified by menopausal status. Nevertheless, menopausal 
status was investigated as a risk factor, which enables us to summarize whether ERPR subtypes 
have a different distribution of menopausal status. Additionally, sample sizes were not 
considered during the review process, and the proportion of ER+PR- and ER-PR+ are relatively 
small. However, this studies still serve as a comprehensive meta-analysis for the associations. In 
light of comprehensive reproductive factors included and its potential applications, strengths 
outweigh limitations. Specifically, regarding preventive guideline, not having children, not 
breastfeeding, birth control, and hormone therapy after menopause increase the risk of BC 
overall according to the American Cancer Society49. However, most of them lack 
recommendations by BC subtypes. Through this study, summarization for the effects of most 
reproductive factors by ERPR subtypes will be available, and the current risk factor pattern could 
possibly be revised. Moreover, the reproductive factors patterns could be combined with family 
history and other risk factors to predict risks of developing specific BC subtypes. Modifiable 
reproductive factors such as breastfeeding could be promoted, especially among populations with 
high incidences of ER+PR+, ER+PR-, and ER-PR- BC subtypes, which have a significant 
association with breastfeeding. Regarding BC screening, the risk assessment tool (the Gail 
model) provided by the National Health Institute only considers age at first birth and age at 
menarche among all reproductive factors. Through this study, other consistent reproductive 
factors such as breastfeeding could possibly be included in this risk calculation model and thus 





This study offers better understanding of the associations between reproductive factors and BC 
ERPR subtypes. Throughout all reproductive factors, age at menarche, pregnancy, and 
breastfeeding showed a relatively consistent finding. Out of four ERPR subtypes, strongest 
associations were observed for ER+PR- subtypes, although more studies with bigger sample 
sizes for ER+PR- and ER-PR+ subtypes should be conducted. With this finding, possible 
preventive guidance and the risk calculation model could be possibly revised. More studies 
stratifying menopausal status are also needed to be conducted to deeply investigated the 
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2011-2017 64 10 6 5 13 
2006-2010 22 5 3 0 5 
2000-2005 12 7 5 4 7 
Data Source 
Primary Data 72 20 12 7 21 
Hospital database 16 1 2 2 3 
National Cancer Database* 
(E.g. SEER, CRN) 
5 0 0 0 0 
State Registry data 5 1 0 0 1 
Region of study 
USA 44 11 9 5 13 
Asia 19 4 3 3 5 
Europe 16 2 1 1 2 
Multi-countries 9 3 0 0 4 
Unknown 5 0 1 0 0 
Africa 3 0 0 0 0 
Australia 1 1 0 0 0 
Canada 1 1 0 0 1 
Exposure of Interest 
Pregnancy/parity 64 13 8 6 15 
Breastfeeding 55 15 8 7 16 
Age at first birth 52 15 10 8 16 
Menarche/menstruation 48 15 8 7 16 
OC** use 28 11 5 4 11 
HRT§ 27 14 6 6 14 
Menopausal status 22 6 7 6 8 
Age at menopause 21 7 4 3 8 
Abortion 7 2 1 1 2 
*SEER: Surveillance, Epidemiology and End Results; CRN: Cancer Registry of Norway 
**OC: Oral Contraceptive 
§ HRT: Hormone replacement therapy 
 







Contrast ER+PR+ ER+PR- ER-
PR+ 
ER-PR- 
Age at menarche Late vs. early S- S- S- S- 
Age at menopause Late vs. early S+ S+ NS+ NS+ 
Menopausal status Post vs. pre/peri S- NS+ S- NS+ 
Pregnancy Ever vs. never S- S- S- NS- 
Age at first birth Nulliparous vs. early age at 
FB 
S+ S- NS- NS- 
Late vs. early S+ S+ NS+ NS- 
Parity Large parity vs. nulliparity S- S- NS- NS- 
Larger vs. smaller S- NS+ NS- NS- 
Breastfeeding Ever vs. never S- S- NS- S- 
Larger vs. smaller NS- S- NS- NO 
Years since last birth Short vs. long NS+ - - NS+ 
OC use Ever vs. never NS- NS+ NS+ NS+ 
HRT Ever vs. never S+ NS+ NO NS+ 













Figure 5. Pregnancy and BC subtypes defined by ERPR status 
 
 
Figure 6. Age at first birth and BC subtypes defined by ERPR status 
 
Figure 7. Parity and BC subtypes defined by ERPR status 
 
Figure 8. Breastfeeding and BC subtypes defined by ERPR status 
 
 







Figure 10. OC use and BC subtypes defined by ERPR status 
 
Figure 11. Hormone replacement therapy and BC subtypes defined by ERPR status 
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